Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01836679 | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 202 | SCRI Development Innovations, LLCOTHER | 1 | Jan 29, 2016 |
| NCT01022671 | Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy | completed | Phase 2 | 52 | Chong Kun Dang PharmaceuticalINDUSTRY | 0 | Jan 28, 2016 | clinicaltrials |
| NCT01137968 | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 116 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT00130780 | Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC | completed | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00588445 | Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00534027 | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 172 | AmgenINDUSTRY | 0 | Jan 14, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT01109524 | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 3 | Dec 24, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | completed | Phase 2 | 37 | Oncolytics BiotechINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00157209 | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | completed | Phase 2 | 171 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01204697 | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | completed | Phase 2 | 74 | Hoffmann-La RocheINDUSTRY | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00112346 | Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 120 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT01924195 | Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） | completed | Phase 2 | 117 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00960115 | Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | completed | Phase 1 / Phase 2 | 178 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 21, 2015 | clinicaltrials |
| NCT01560104 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 160 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Oct 21, 2015 | clinicaltrials |
| NCT01100931 | A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | completed | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00743938 | A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | completed | Phase 2 | 141 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT01167244 | Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response | completed | Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT01077713 | A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 86 | Hoffmann-La RocheINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01633645 | Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | University Hospital of CreteOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01852578 | Cabazitaxel in Relapsed and Metastatic NSCLC | completed | Phase 2 | 46 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01628471 | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 20 | Uman PharmaINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00178256 | Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer | completed | Phase 1 / Phase 2 | 41 | University of RochesterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00157196 | Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease | completed | Phase 2 | 22 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | Aug 18, 2015 | clinicaltrials |
| NCT00269152 | Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer | completed | Phase 2 | 122 | Eli Lilly and CompanyINDUSTRY | 3 | Aug 18, 2015 | clinicaltrials |
| NCT01580735 | ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer | completed | Phase 2 | 40 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Aug 18, 2015 | clinicaltrials |
| NCT01243775 | BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC(BELOXAN) | completed | Phase 2 | 33 | Chonnam National University HospitalOTHER | 1 | Aug 17, 2015 | clinicaltrials |
| NCT00732810 | SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | completed | Phase 2 | 97 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 5, 2015 | clinicaltrials |
| NCT01204307 | Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation | completed | Phase 2 | 101 | Chang Gung Memorial HospitalOTHER | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00063154 | Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy | completed | Phase 2 | 51 | Genentech, Inc.INDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT01011075 | Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer(6137p) | completed | Phase 2 | 34 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 3, 2015 | clinicaltrials |
| NCT00867009 | A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 113 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 15, 2015 | clinicaltrials |
| NCT00621049 | Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC | completed | Phase 2 | 112 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01562015 | A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)(CHIARA) | completed | Phase 2 | 12 | Synta Pharmaceuticals Corp.INDUSTRY | 2 | May 20, 2015 | clinicaltrials |
| NCT00892710 | Trial of Poor Performance Status Patients (ToPPS)(ToPPS) | completed | Phase 2 | 172 | SCRI Development Innovations, LLCOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT02175381 | Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 69 | Hellenic Oncology Research GroupOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT02154399 | EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT00078455 | Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00531934 | A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. | completed | Phase 2 | 147 | Hoffmann-La RocheINDUSTRY | 1 | Feb 25, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2016source: clinicaltrials